Ionis Pharmaceuticals, Inc. Debt Securities, Available-for-sale, Amortized Cost
Ionis Pharmaceuticals, Inc. (IONS) had Debt Securities, Available-for-sale, Amortized Cost of $1.79 billion as of 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Notes › Debt Securities, Available-for-Sale, Amortized Cost
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-07-29
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $1.79B.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $1.75B.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $2.35B.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $1.98B.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-06-30 | $1.79B 10-Q · filed 2026-07-29 |
| 2026-03-31 | $1.75B 10-Q · filed 2026-04-29 |
| 2025-12-31 | $2.35B 10-Q · filed 2026-07-29 |
| 2025-09-30 | $1.98B 10-Q · filed 2025-10-29 |
| 2025-06-30 | $2.05B 10-Q · filed 2025-07-30 |
| 2025-03-31 | $1.91B 10-Q · filed 2025-04-30 |
| 2024-12-31 | $2.06B 10-K · filed 2026-02-26 |
| 2024-09-30 | $2.18B 10-Q · filed 2024-11-06 |
| 2024-06-30 | $1.81B 10-Q · filed 2024-08-01 |
| 2024-03-31 | $1.88B 10-Q · filed 2024-05-07 |
| 2023-12-31 | $1.97B 10-K · filed 2025-02-19 |
| 2023-09-30 | $1.90B 10-Q · filed 2023-11-02 |
| 2023-06-30 | $2.02B 10-Q · filed 2023-08-09 |
| 2023-03-31 | $2.06B 10-Q · filed 2023-05-03 |
| 2022-12-31 | $1.75B 10-K · filed 2024-02-21 |
| 2022-09-30 | $1.73B 10-Q · filed 2022-11-09 |
| 2022-06-30 | $1.55B 10-Q · filed 2022-08-09 |
| 2021-12-31 | $1.25B 10-K · filed 2023-02-22 |
| 2015-12-31 | $660.46M 10-K · filed 2016-02-26 |
| 2014-12-31 | $606.89M 10-K · filed 2016-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |